DOCSLIB.ORG

Meeting Program

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Meeting Program BOARD OF DIRECTORS Linda J. Porrino, PhD, President David A. Fiellin, MD Sharon Walsh, PhD, Past-President Leonard L. Howell, PhD Anna Rose Childress, PhD, President-Elect Scott E. Lukas, PhD Stephen G. Holtzman, PhD, Treasurer Geoffrey K. Mumford, PhD Patrick M. Beardsley, PhD Michael A. Nader, PhD Lawrence S. Brown, MD, MPH Edward V. Nunes, MD Steven R. Childers, PhD Richard A. Rawson, PhD Theodore J. Cicero, PhD Maxine L. Stitzer, PhD Sandra D. Comer, PhD Eric C. Strain, MD Richard De La Garza, II, PhD Dace S. Svikis, PhD EXECUTIVE OFFICER Martin W. Adler, PhD SCIENTIFIC PROGRAM COMMITTEE Sari Izenwasser, PhD, Chair Martin W. Adler, PhD, ex officio Ellen B. Geller, MA, ex officio Alan J. Budney, PhD Howard D. Chilcoat, ScD Sandra D. Comer, PhD Patrick M. Flynn, PhD Cindy Kuhn, PhD Michelle R. Lofwall, MD Lance R. McMahon, PhD Janet L. Neisewander, PhD Jennifer W. Tidey, PhD Ellen M. Unterwald, PhD Elise M. Weerts, PhD PRE-MEETING SATELLITES NIDA: Application of Genetic Approaches to Understand Sonoran Drug Abuse and Addiction June 11 Chaired by Minda R. Lynch and David Shurtleff Third Meeting of the International Women’s and Children’s Salon BC Health and Gender Group June 11 Chaired by Frances E. Ashe-Goins and Wendee Wechsberg The 14th Annual NIDA International Forum on Sonoran Drug Abuse Research, Policy and the Public Good June 11 - 12 Chaired by Steven Gust Addiction Studies Program for Journalists (ASPJ) McDowell (By Invitation Only) June 11 - 12 The International Study Group Investigating Salon D Drugs as Reinforcers (ISGIDAR) June 12 Chaired by S. Barak Caine 10 th Annual Meeting Center for Substance Abuse Salon BC Treatment (CSAT) June 12 Chaired by Peter Edwards 2010 AAAP Addiction Board Review Course at CPDD: Salon F A Clinical Review of Substance Use Disorders June 12 CPDD REGISTRATION Conference Center – East Foyer Saturday, June 12 1:30 PM - 5:30 PM Sunday, June 13 8:00 AM - 12:00 PM 1:30 PM - 5:00 PM Monday, June 14 9:00 AM - 12:30 PM 1:30 PM - 5:00 PM Tuesday, June 15 11:00 AM - 5:00 PM Wednesday, June 16 9:00 AM - 11:00 PM 2:00 PM - 5:00 PM Thursday, June 17 8:00 AM - 1:00 PM OPENING RECEPTION (Cash Bar) Hacienda Plaza Saturday, June 12 7:00 PM - 9:00 PM (Pre-registrants can pick up badges only) Sunday, June 13, 2010 CSAT Travel Awards Breakfast Princesa (By Invitation Only) 7:00 - 8:00 AM Plenary Session Salons DEFG 8:45 - 11:30 AM 8:45 Welcome, CPDD President Linda Porrino 8:55 Report from the National Institute on Drug Abuse Nora D. Volkow, NIDA, Bethesda, MD 9:25 Drug Strategies and Potential for Research Opportunities A. Thomas McLellan, Deputy Director for Demand Reduction, ONDCP, Bethesda, MD 9:55 Presentation of the Distinguished Service Award to Jack Henningfield Introduction by Sharon Walsh 10:00 Presentation of the Media Award to Allan Brandt Introduction by Marc Kaufman 10:05 Presentation of the J. Michael Morrison Award to Cora Lee Wetherington Introduction by Marilyn Carroll 10:10 Presentation of the Joseph Cochin Young Investigator Award to David Jentsch Introduction by Edythe London 10:15 Presentation of the Mentorship Award to Charles O’Brien Introduction by Anna Rose Childress 10:20 Presentation of the Nathan B. Eddy Award to Theodore Cicero Introduction by Linda Cottler 10:30 Nathan B. Eddy Award Lecture by Theodore Cicero Early Career Investigator Awards Luncheon La Hacienda (By Invitation Only) 12:00 - 1:30 PM President’s Lecture Salons DEFG 1:30 - 2:30 PM GENE X ENVIRONMENT INTERACTIONS IN PRIMATES Stephen J. Suomi, National Institutes of Health, DHHS Symposium I Salons HI 3:00 - 5:00 PM TRANSLATING THE GENETICS AND NEUROCHEMISTRY OF NICOTINE DEPENDENCE TO DRUG DEVELOPMENT Chairs: Linda Porrino and Joni L. Rutter 3:00 Genetic variation in nicotine metabolism and implications for targeted therapy for nicotine addiction Caryn Lerman, Psychiatry, University of Pennsylvania, Philadelphia, PA 3:25 Genetics of nicotine dependence and the convergence with lung cancer and chronic obstructive pulmonary disease Laura Bierut, Washington University at St. Louis, St. Louis, MO 1 Sunday, June 13, 2010 3:50 Alpha-5-containing nicotinic acetylcholine receptors transmit a negative reward signal that controls nicotine intake Paul Kenny, Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL 4:15 The influence of the Alpha-5 subunit on the regulation of brain nicotinic cholinergic receptors by nicotine Ken Kellar, Pharmacology, Georgetown University School of Medicine, Washington, DC 4:40 Discussant Nora Volkow, National Institute on Drug Abuse, Bethesda, MD Symposium II Salons ABC 3:00 - 5:00 PM CPDD INTERNATIONAL COMMITTEE SYMPOSIUM: A COMPREHENSIVE APPROACH TO EXAMINE THE USE AND IMPACT OF CANNABIS: FROM BRAIN EFFECTS TO EPIDEMIOLOGICAL IMPACT ACROSS THE WORLD Chairs: Flavio Pechansky and Alison Ritter 3:00 Cognitive effects of cannabinoids: Lessons from animal models Marco Bortolato, Neurological Science, University of Cagliari, Monserrato, Italy 3:25 Is cannabis smoking harmful? Epidemiological perspectives and evidence on this question James C. Anthony, Epidemiology, Michigan State University, East Lansing, MI 3:50 Periadolescent cannabinoid exposure effects on self-administration behavior and several neurotransmitter systems in the adulthood Emilio Ambrosio Flores, Psychobiology, UNED-Ciudad Universitaria Madrid, Madrid, Spain 4:15 Imaging trials of cannabis users in South Africa Paul Carey, Psychiatry, University of Stellenbosch, Stellenbosch, South Africa 4:40 Discussant Jan Copeland, National Cannabis Prevention and Information Centre, University of New South Wales, Sydney, NSW, Australia Oral Communications 1 Salon DE 3:00 - 5:00 PM WHAT’S NEW WITH MU? HUMAN LABORATORY RESEARCH WITH OPIOIDS Chairs: Mark Greenwald and Bethea A. Kleykamp 3:00 Yohimbine increases opioid-seeking behavior in buprenorphine-stabilized, heroin-dependent volunteers M. Greenwald, C. L. Steinmiller, Psychiatry, Wayne State University, Detroit, MI 3:15 Pharmacodynamic and pharmacokinetic profile of crushed intranasal Suboxone® and Subutex® in sporadic opioid abusers L. S. Middleton1, P.A. Nuzzo1, M. R. Lofwall1,2, D. E. Moody3, M. J. Wunsch1,2, S. L. Walsh1,2, 1Behavioral Science/Center on Drug & Alcohol Research, and 2Psychiatry, University of Kentucky, Lexington, KY, 3Center for Human Toxicology, University of Utah, Salt Lake City, UT 2 Sunday, June 13, 2010 3:30 Oral intact extended-release oxymorphone has fewer subjective and cognitive effects than equianalgesic controlled-release oxycodone S. O. McMorn1, K. A. Schoedel2, B. Chakraborty2, E. M. Sellers2, 1Endo Pharmaceuticals Inc., Chadds Ford, PA, 2Kendle Early Stage, Toronto, ON, Canada 3:45 The effect of methadone on emotional reactivity S. Savvas, A. A. Somogyi, J. M. White, Adelaide University, Adelaide, SA, Australia 4:00 Effects of methadone alone and in combination with alcohol on cognitive performance in methadone-maintained volunteers B. A. Kleykamp, R. G. Vandrey, G. E. Bigelow, E. C. Strain, M. Z. Mintzer, Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD 4:15 The effects of the opiate neutral antagonist 6β-naltrexol in opiate-dependent subjects J. Mendelson1, K. Flower1, M. Jang1, C. W. Harris1, W. Sadee2, W. Snape1, G. P. Galloway1, 1Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA, 2Pharmacology, Ohio State University, Columbus, OH 4:30 Effects of cycloserine and gabapentin in methadone-maintained humans under a naloxone novel-response discrimination procedure A. Oliveto1, W. B. Gentry1, J. B. Guise1, C. Cargile2, W. K. Bickel1, M. J. Mancino1, 1Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, 2Psychiatry, Texas A & M Health Science Center, College Station, TX 4:45 Assessing temptations to use heroin and cocaine during drug detoxification using ecological momentary assessment A. J. Waters1, I. Franken2, R. Marhe2, 1Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, Bethesda, MD, 2Psychology, Erasmus University, Rotterdam, Netherlands Oral Communications 2 Salon FG 3:00 - 5:00 PM UP FRONT WITH DRUG ADDICTION: ROLE OF FRONTAL CORTEX Chairs: Anna R. Childress and Hedy Kober 3:00 Blockade of 5-HT2A receptors in the medial prefrontal cortex attenuates cue-elicited reinstatement of cocaine-seeking behavior in rats L. A. Pockros, N. S. Pentkowski, S. E. Swinford, L. M. Robertson, M. Ostos, J. L. Neisewander, Arizona State University, Tempe, AZ 3:15 BDNF in the prefrontal cortex: Involvement in psychostimulant- and social defeat stress-induced behavioral sensitization E. Nikulina1,2, M. Lacagnina1, J. Wang2, S. Fanous1, R. Hammer, Jr1,2, 1Basic Medical Sciences, University of Arizona, College of Medicine -Phoenix, Phoenix, AZ, 2Neuroscience, Arizona State University, Tempe, AZ 3:30 Psychostimulant drug effects on spike train coding of sensory and decision-related signals in rodent thalamic and cortical circuits during quiet resting and sustained attention B. Waterhouse, K. L. Agster, B. D. Clark, J. S. Shumsky, Neurobiology & Anatomy, Drexel University College of Medicine, Philadelphia, PA BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS 3 Sunday, June 13, 2010 3:45 Impaired fronto-amygdalar connectivity: A marker of poor behavioral control in cocaine dependence? J. J. Suh1,2, R. Ehrman1,2, Y. Li1, Z. Wang1, D. Willard1, R. Fabianski1, R. Carson1, R. Hazan1, A. Fornash1, M. Goldman1, T. Franklin1, A. V.Hole1,2, R. Szucs1,2, C. P. O’Brien1,2, A. R. Childress1,2, 1University of Pennsylvania School of Medicine, and 2VA VISN4 MIRECC, Philadelphia, PA 4:00 Changes in brain activation pattern during cue reactivity after one month abstinence in heroin dependents H. Ganjgahi1, P. Hasani Abharian1,2, J. Mc Clernon4, Z. Alam Mehrjerdi1, H. Tabatabaei1, M. Oghabian3, H. Ekhtiari1, 1Neurocognitive, Iranian National Center for Addiction Studies, 2Institute for Cognitive Sciences Studies, and 3Neuroimaging, Research Center for Science and Technologies, Tehran, Islamic Republic of Iran, 4Center for Nicotine and Smoking Cessation Research, Duke University Medical Center, Durham, NC 4:15 Relationship of impulsive personality traits and orbitofrontal rCBF in cocaine-addicted and healthy subjects J.
Load more

Recommended publications
  • Cuyahoga County Opioid Use Disorder Information & Resource
    Cuyahoga County Opioid Use Disorder Information & Resource Guide Developed by the MetroHealth Office of Opioid Safety’s First Responders Project 815588MH_Booklet.indd 1 9/25/18 7:42 AM Table of Contents What is Opioid Use Disorder .................................................. 1 Assessments ............................................................................. 1 TREATMENT Treatment Overview ............................................................... 2 Counseling ............................................................................. 3 Opioid Withdrawal .............................................................. 3 Medication Assisted Treatment – How Does it Work? ................................................................. 4 - Buprenorphine Medication Assisted Treatment - Methadone Medication Assisted Treatment - Naltrexone Medication Assisted Treatment Inpatient Treatment .................................................................. 6 Outpatient Treatment ................................................................ 6 RECOVERY Recovery Housing .................................................................. 7 Recovery Support Groups ...................................................... 7 PROGRAMS AND SERVICES Harm Reduction ..................................................................... 8 Project DAWN .......................................................................... 8 Naloxone in Pharmacies with a Prescription .......................... 9 Syringe Exchange Program ..................................................
    [Show full text]
  • Director's Report May 2016
    TABLE OF CONTENTS RESEARCH HIGHLIGHTS ................................................................................................. 1 GRANTEE HONORS AND AWARDS .............................................................................. 22 STAFF HONORS AND AWARDS .................................................................................... 23 STAF F CHANGES ............................................................................................................ 24 RESEARCH HIGHLIGHTS BASIC AND BEHAVIORAL RESEARCH Self-administration Of the Anandamide Transport Inhibitor AM404 By Squirrel Monkeys Schindler CW, Scherma M, Redhi GH, Vadivel SK, Makriyannis A, Goldberg S, Justinova Z. Psychopharmacology (Berl). 2016; [epub ahead of print]. N-(4-hydroxyphenyl)-arachidonamide (AM404) is an anandamide transport inhibitor shown to reduce rewarding and relapse-inducing effects of nicotine in several animal models of tobacco dependence. However, the reinforcing/rewarding effects of AM404 are not clear. The authors investigated whether AM404 maintains self-administration behavior or reinstates extinguished drug seeking in squirrel monkeys. In monkeys with a history of anandamide or cocaine self- administration, we substituted injections of AM404 (1-100 μg/kg/injection). Using a 10-response, fixed-ratio schedule, self-administration behavior was maintained by AM404. Dose-response curves had inverted U shapes, with peak response rates occurring at a dose of 10 μg/kg/injection. In anandamide-experienced monkeys, we also demonstrated
    [Show full text]
  • Epigenetic Regulation of Circadian Clocks and Its Involvement in Drug Addiction
    G C A T T A C G G C A T genes Review Epigenetic Regulation of Circadian Clocks and Its Involvement in Drug Addiction Lamis Saad 1,2,3, Jean Zwiller 1,4, Andries Kalsbeek 2,3 and Patrick Anglard 1,5,* 1 Laboratoire de Neurosciences Cognitives et Adaptatives (LNCA), UMR 7364 CNRS, Université de Strasbourg, Neuropôle de Strasbourg, 67000 Strasbourg, France; [email protected] (L.S.); [email protected] (J.Z.) 2 The Netherlands Institute for Neuroscience (NIN), Royal Netherlands Academy of Arts and Sciences (KNAW), 1105 BA Amsterdam, The Netherlands; [email protected] 3 Department of Endocrinology and Metabolism, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands 4 Centre National de la Recherche Scientifique (CNRS), 75016 Paris, France 5 Institut National de la Santé et de la Recherche Médicale (INSERM), 75013 Paris, France * Correspondence: [email protected]; Tel.: +33-03-6885-2009 Abstract: Based on studies describing an increased prevalence of addictive behaviours in several rare sleep disorders and shift workers, a relationship between circadian rhythms and addiction has been hinted for more than a decade. Although circadian rhythm alterations and molecular mechanisms associated with neuropsychiatric conditions are an area of active investigation, success is limited so far, and further investigations are required. Thus, even though compelling evidence connects the circadian clock to addictive behaviour and vice-versa, yet the functional mechanism behind this interaction remains largely unknown. At the molecular level, multiple mechanisms have been proposed to link the circadian timing system to addiction. The molecular mechanism of the circadian Citation: Saad, L.; Zwiller, J.; clock consists of a transcriptional/translational feedback system, with several regulatory loops, that Kalsbeek, A.; Anglard, P.
    [Show full text]
  • Regional Alcohol and Drug Detoxification Manual 2019
    Regional Alcohol and Drug Detoxification Manual 2019 Arkansas Department of Human Services Division of Aging, Adult and Behavioral Health Services Office of the Drug Director RADD Regional Alcohol and Drug Detoxification Regional Alcohol and Drug Detoxification Manual Office of the Drug Director P.O. Box 1437, Slot W-241 Little Rock, Arkansas 72203 501-686-9164 501-686-9396 (fax) 1 Regional Alcohol and Drug Detoxification Manual 2019 2 Regional Alcohol and Drug Detoxification Manual 2019 Contents Regional Alcohol and Drug Detoxification Program ......................................................................................................... 5 Chapter 1 ........................................................................................................................................................................... 7 Overview, Essential Concepts, and Definitions in Detoxification ...................................................................................... 7 Chapter 2 ......................................................................................................................................................................... 12 Settings, Levels of Care, and Patient Placement ............................................................................................................... 12 Chapter 3 ......................................................................................................................................................................... 22 An Overview of Psychosocial and Biomedical
    [Show full text]
  • Stage of Change of Cigarette Smoking in Drug Dependent Patients
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE Original article SWISS MED WKLY 2004;134:322–325provided · www.smw.ch by Serveur académique322 lausannois Peer reviewed article Stage of change of cigarette smoking in drug dependent patients Stéphane Kollya, Jacques Bessona, Jacques Cornuzb, Daniele Fabio Zullinoa a Division of Substance Abuse, University Department of Adult Psychiatry, Lausanne, Switzerland b Lausanne University Outpatient Clinic and Institute of Social and Preventive Medicine, Lausanne, Switzerland Summary Nicotine cessation programmes in Switzer- cessation to be difficult or very difficult. These data land, which are commonly based on the stage of show a discrepancy between the motivation to change model of Prochaska and DiClemente change illegal drug consumption habits and the (1983), are rarely offered to patients with illicit motivation for smoking cessation. The high pro- drug dependence. This stands in contrast to the portion of patients remaining in the precontem- high smoking rates and the heavy burden of to- plation stage for smoking cessation, in spite of their bacco-related problems in these patients. motivation for illicit drug detoxification, may be The stage of change was therefore assessed by due to the perception that cessation of smoking is self-administered questionnaire in 100 inpatients more difficult than illicit drug abuse cessation. attending an illegal drug withdrawal programme. Only 15% of the patients were in the contempla- Key words: substance abuse; smoking; smoking ces- tion or decision stage. 93% considered smoking sation; motivation Introduction The prevalence of smoking has consistently have lower smoking cessation rates [17]. On the been stated to be higher in drug-dependent pa- other hand, efforts to stop smoking have been tients than in the general population.
    [Show full text]
  • Acupuncture for Detoxification in Treatment of Opioid Addiction
    East Asian Arch Psychiatry 2016;26:70-6 Theme Paper Acupuncture for Detoxification in Treatment of Opioid Addiction SLY Wu, AWN Leung, DTW Yew Abstract Opioid is a popular drug of abuse and addiction. We evaluated acupuncture as a non-pharmacological treatment with a focus on managing withdrawal symptoms. Electrical stimulation at a low frequency (2 Hz) accelerates endorphin and encephalin production. High-frequency stimulation (100 Hz) up- regulates the dynorphin level that in turn suppresses withdrawal at the spinal level. The effect of 100-Hz electroacupuncture may be associated with brain-derived neurotrophic factor activation at the ventral tegmental area, down-regulation of cAMP response element-binding protein, and enhanced dynorphin synthesis in the spinal cord, periaqueductal grey, and hypothalamus. Clinical trials of acupuncture for the management of different withdrawal symptoms were reviewed. The potential of acupuncture to allay opioid-associated depression and anxiety, and its possible use as an adjuvant treatment were evident. A lack of effect was indicated for opioid craving. Most studies were hampered by inadequate reporting details and heterogeneity, thus future well-designed studies are needed to confirm the efficacy of acupuncture in opioid addiction treatment. Key words: Acupuncture; Electroacupuncture; Heroin; Opioid-related disorders; Substance withdrawal syndrome Ms Sharon L. Y. Wu, BSc, MCM, School of Chinese Medicine, The Chinese dominant treatment of detoxification.6 Nevertheless, MMT University of Hong Kong, Hong Kong SAR, China. Prof. Albert Wing-Nang Leung, BSc, PhD, BCM, School of Chinese Medicine, is a substitution therapy and contributes to a high relapse The Chinese University of Hong Kong, Hong Kong SAR, China.
    [Show full text]
  • Safe Withdrawal in Jail Settings Preventing Deaths, Reducing Risk to Counties and States
    Safe Withdrawal in Jail Settings Preventing Deaths, Reducing Risk to Counties and States This brief is for jail administrators and other public safety leaders, as well as county and state policymakers who work on issues related to public safety, public health, and behavioral health. Jail administrators and policymakers are responsible for managing health issues of those incarcerated in their facilities. As the opioid crisis continues, jails may face a growing need to save detainee lives and reduce their own exposure to litigation risk by ensuring safe withdrawal from illicit drugs and alcohol. This document addresses the need for withdrawal management procedures and services in jail settings. Overview As the opioid crisis continues, jails across the country are encountering people with opioid use disorders who are actively using heroin, fentanyl, illicit prescription medications, and other opioids. These individuals often experience withdrawal syndrome upon abrupt substance discontinuation, and they may need withdrawal management services while detained.1,2,3,4 Withdrawal syndrome can occur with discontinuation of non-opioid substances as well, including alcohol and benzodiazepines. Contrary to commonly held notions, withdrawal is often not only uncomfortable or painful, but also may be harmful to health and even fatal.5,6,7 Jails without adequate services and protocols for withdrawal management face risk liability under state statutes and tort law, the Americans with Disabilities Act (“ADA”), Rehabilitation Act of 1973 (“Rehabilitation
    [Show full text]
  • Treatment for Alcohol and Other Drug Abuse: Opportunities for Coordination
    Treatment for Alcohol and Other Drug Abuse: Opportunities for Coordination Technical Assistance Publication Series 11 Ann H. Crowe, M.S.S.W., A.C.S.W. Rhonda Reeves, M.A. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment Rockwall II, 5600 Fisher Lane Rockville, MD 20857 Foreword of TAP 11: Treatment for Alcohol and Other Drug Abuse: Opportunities for Coordination This publication is part of the Substance Abuse Prevention and Treatment Block Grant technical assistance program. All material appearing in this volume except quoted passages from copyrighted sources is in the public domain and may be reproduced or copied without permission from the Center for Substance Abuse Treatment (CSAT) or the author. Citation of the source is appreciated. This publication was written by Ann H. Crowe, M.S.S.W., A.C.S.W., and Rhonda Reeves, M.A., of the Council of State Governements. Contributors to the publication were Thomas B. Kosten, M.D., of the Department of Psychiatry, Division of Substance Abuse, Yale University School of Medicine, and Bert Pepper, M.D., and Jackie Massaro, C.S.W., of the Information Exchange. It was prepared under contract number 270-92-0007 from the Substance Abuse and Mental Health Services Administration (SAMHSA). Roberta Messalle of CSAT served as the Government project officer. The opinions expressed herein are the views of the authors and do not necessarily reflect the official position of CSAT or any other part of the U.S. Department of Health and Human Services (DHHS).
    [Show full text]
  • Opioid-Related US Hospital Discharges by Type, 1993–2016
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author J Subst Manuscript Author Abuse Treat. Author Manuscript Author manuscript; available in PMC 2019 August 01. Published in final edited form as: J Subst Abuse Treat. 2019 August ; 103: 9–13. doi:10.1016/j.jsat.2019.05.003. Opioid-related US hospital discharges by type, 1993–2016 Cora Peterson*, Likang Xu, Curtis Florence, and Karin A. Mack National Center for Injury Prevention and Control, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA Abstract Objective: To classify and compare US nationwide opioid-related hospital inpatient discharges over time by discharge type: 1) opioid use disorder (OUD) diagnosis without opioid overdose, detoxification, or rehabilitation services, 2) opioid overdose, 3) OUD diagnosis or opioid overdose with detoxification services, and 4) OUD diagnosis or opioid overdose with rehabilitation services. Methods: Survey-weighted national analysis of hospital discharges in the Healthcare Cost and Utilization Project National Inpatient Sample yielded age-adjusted annual rates per 100,000 population. Annual percentage change (APC) in the rate of opioid-related discharges by type during 1993–2016 was assessed. Results: The annual rate of hospital discharges documenting OUD without opioid overdose, detoxification, or rehabilitation services quadrupled during 1993–2016, and at an increased rate (8% annually) during 2003–2016. The discharge rate for all types of opioid overdose increased an average 5–9% annually during 1993–2010; discharges for non-heroin overdoses declined 2010– 2016 (3–12% annually) while heroin overdose discharges increased sharply (23% annually). The rate of discharges including detoxification services among OUD and overdose patients declined (−4% annually) during 2008–2016 and rehabilitation services (e.g., counselling, pharmacotherapy) among those discharges decreased (−2% annually) during 1993–2016.
    [Show full text]
  • Cigarette Smoking, Nicotine Dependence, and Treatment
    578 I || Addiction Medicinel and the Primary Care Phlysician Cigarette Smoking, Nicotine Dependence, and Treatment KAREN LEA SEES, DO, San Francisco Since the 1988 Surgeon General's report on nicotine addiction, more attention is being given to nicotine dependence as a substantial contributing factorin cigarette smokers' inability to quit. Manynew medica- tions are being investigated for treating nicotine withdrawal and for assisting in long-term smoking abstinence. Medications alone probably will not be helpful; they should be used as adjuncts in compre- hensive smoking abstinence programs that address not only the physical dependence on nicotine but also the psychological dependence on cigarette smoking. (Sees KL: Cigarette smoking, nicotine dependence, and treatment, In Addiction Medicine [Special Issue]. West J Med 1990 May; 152:578-584) Physicians have long been frustrated in attempts to DSM-III-R Diagnostic Criteria for Psychoactive Substance help patients stop smoking, and, until recently, they Dependence have had few tools other than advice. Cigarette smoking and now ac- * Substance often taken in larger amounts or over a other forms of tobacco consumption, however, are the person intended. knowledged as causing nicotine dependence, and with that longer period than recognition comes the acceptance oftreating tobacco use not * Persistent desire or one or more unsuccessful efforts to merely as a bad habit, or nasty vice, but as the disease of cut down or control substance use. Most cigarette smokers nicotine addiction. The recognition
    [Show full text]
  • Drug Detoxification Protocol Using Microdosing
    (19) & (11) EP 2 399 581 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 28.12.2011 Bulletin 2011/52 A61K 31/485 (2006.01) A61K 31/49 (2006.01) A61K 31/554 (2006.01) A61K 9/20 (2006.01) (21) Application number: 11170065.4 (22) Date of filing: 15.02.2008 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • Slater, Kenneth C. HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT Manchester MA 01944 (US) RO SE SI SK TR • Richardson, Brenda E. Manchester MA 01944 (US) (30) Priority: 15.02.2007 US 675560 • Connors, Scott M. Methuen MA 01844 (US) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: (74) Representative: Richaud, Fabien 08002803.8 / 1 958 621 Murgitroyd & Company Immeuble Atlantis (71) Applicants: 55, Allée Pierre Ziller • Slater, Kenneth C. 06560 Valbonne Sophia Antipolis (FR) Manchester MA 01944 (US) • Richardson, Brenda E. Remarks: Manchester MA 01944 (US) This application was filed on 15-06-2011 as a • Connors, Scott M. divisional application to the application mentioned Methuen MA 01844 (US) under INID code 62. (54) Drug detoxification protocol using microdosing (57) This invention relates to use of an opioid recep- the withdrawal symptoms associated with discontinuing tor agonist in microdose quantities to reduce or eliminate drug use. The dosage of the agonist is reduced over an extended period of time. EP 2 399 581 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 399 581 A1 Description FIELD OF THE TECHNOLOGY 5 [0001] This invention relates to methods to decrease the withdrawal symptoms a patient suffers of discontinuing drug use.
    [Show full text]
  • National Trends and Characteristics of Inpatient Detoxification for Drug Use Disorders in the United States He Zhu1* and Li-Tzy Wu1,2,3,4*
    Zhu and Wu BMC Public Health (2018) 18:1073 https://doi.org/10.1186/s12889-018-5982-8 RESEARCH ARTICLE Open Access National trends and characteristics of inpatient detoxification for drug use disorders in the United States He Zhu1* and Li-Tzy Wu1,2,3,4* Abstract Background: Prior studies indicate that the opportunity from detoxification to engage in subsequent drug use disorder (DUD) treatment may be missed. This study examined national trends and characteristics of inpatient detoxification for DUDs and explored factors associated with receiving DUD treatment (i.e., inpatient drug detoxification plus rehabilitation) and discharges against medical advice (DAMA). Methods: We analyzed inpatient hospitalization data involving the drug detoxification procedure for patients aged≥12 years (n = 271,403) in the 2003–2011 Nationwide Inpatient Samples. We compared the estimated rate and characteristics of inpatient drug-detoxification hospitalizations between 2003 and 2011 and determined demographic and clinical correlates of inpatient drug detoxification plus rehabilitation (versus detoxification-only) and DAMA (versus transfer to further treatment). Results: There was no significant yearly change in the population rate of inpatient drug-detoxification hospitalizations during 2003–2011. The majority of inpatient drug detoxification were patients aged 35–64 years, males, and those on Medicaid. Among inpatient drug-detoxification hospitalizations, only 13% received detoxification plus rehabilitation during inpatient care, and up to 14% were DAMA; the most commonly identified diagnoses were opioid use disorder (OUD; 75%) and non-addiction mental health disorders (48%). Being on Medicaid (vs. having private insurance) and having OUD (vs. no OUD) were associated with decreased odds of receiving detoxification plus rehabilitation, as well as increased odds of DAMA.
    [Show full text]